Many drugs are promoted for the treatment of intermittent claudication: cinnarizine (Stugeron Forte), cyclandelate (Cyclospasmol), naftidrofuryl (Praxilene), inositol nicotinate (Hexopal) and oxpentifylline (Trental); two other nicotinic acid derivatives, Bradilan and Ronicol, are licensed but not promoted. In 1988 the Committee on Review of Medicines deleted claudication as an indication for isoxsuprine (Duvadilan) from the product licence because evidence of efficacy was insufficient, but the CRM has been very slow to review the efficacy of the other drugs. Is there evidence that any of these drugs improve walking distance more than placebo?1,2,3
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.